Table 1.
Patient characteristics
| Characteristics | N = 42 |
|---|---|
| Female (%) | 18 (43) |
| Age (years) | 57.30 ± 9.29 |
| BMI (kg/m2) | 24.40 ± 2.71 |
| Follow up time (months) | 6 (2–8) |
| Medical background | |
| Diabetes (%) | 6 (14) |
| Hypertension (%) | 15(36) |
| Thyroid | |
| Hyperthyroidism (%) | 38 (90) |
| Hypothyroidism (%) | 1 (2) |
| Normal (%) | 3 (7) |
| Duration of Thyroid dysfunction (months) | 12 (7.75–36) |
| Duration of TAO (months) | 10.5 (6–12) |
| Duration of DON (months) | 6 (2–11) |
| Serum | |
| FT3 (pg/ml) | 5.27 (4.44–5.94) |
| FT4 (ng/dl) | 17.25 (13.5–20.94) |
| TSH (μIU/ml) | 0.94 (0.08–3.78) |
| TG (ng/ml) | 43.47 (10.44–181) |
| TGAb (IU/ml) | 12.05 (10–18.44) |
| TPOAb (IU/ml) | 21.55 (11.32–56.16) |
BMI= body mass index, TAO= thyroid associated ophthalmopathy, DON= dysthyroid optic neuropathy, FT3= free triiodothyronine, FT4= free thyroxinem, TSH= thyroid stimulating hormone, TG= thyroglobulin, TGAb= thyroglobulin antibody, TPOAb= thyroid peroxidase antibody